Related Experiment Video
Updated: Apr 4, 2026
Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Corticosteroid therapy for severe acute pancreatitis: a meta-analysis of randomized, controlled trials
Li-Hua Dong1, Zhong-Min Liu2, Shi-Ji Wang2
1Intensive Care Unit, First Affiliated Hospital of Jilin University Changchun 130021, China ; Intensive Care Unit, Second Affiliated Hospital of Jilin University Changchun 130041, China.
Background:
Recent reports about the benefits of corticosteroid therapy in patients with severe acute pancreatitis (SAP) have shown conflicting results. We aimed to explore the effects of corticosteroid therapy in SAP patients on patient outcomes by performing a meta-analysis.
Methods:
Databases (Medline, EMBASE, Web of Science, PubMed, Cochrane Library, Chinese Biomedicine Database, and China Academic Journal Full-Text Database) were queried for all relevant, randomized, controlled trials investigating corticosteroid therapy in patients with SAP.
Results:
Six randomized, controlled trials including 430 SAP patients were identified. Corticosteroid therapy for SAP was associated with reductions in the length of hospital stay, the need for surgical intervention, and the mortality rate (weighted mean difference [WMD]: -9.47, 95% confidence interval [CI]: -16.91 to -2.04, P = 0.01; odds ratio [OR]: 0.35, 95% CI: 0.18-0.67, P = 0.002; OR: 0.45, 95% CI: 0.22-0.94, P = 0.03). There were no significant differences in the complication rates or Physiology and Chronic Health Evaluation II (APACHE II) scores in patients with or without corticosteroid therapy.
Conclusion:
Corticosteroid therapy may improve outcomes in patients with SAP.
